N. Almeida*, D. Gomes1, C. Gonçalves2, C. Gregório1, D. Brito1, J. Carlos Campos3, H. Gouveia1, D. Freitas1
Resumo
Introdução: Nos doentes com obesidade mórbida o balão intragástrico (BIG) pode ser uma ponte para a cirurgia ou uma terapêutica temporária nos não candidatos à mesma.
Objectivo: Avaliar a eficácia do BIG em doentes com obesidade severa.
Doentes e Métodos: Em 2003/2004 foram colocados 17 BIG Bioenterics® preenchidos com soro fisiológico e azul-demetileno [volume médio-508,8 ml (450-600)] em 17 doentes [11 mulheres; média etária-49,2 (27-69 anos); Índice de Massa Corporal médio-55,6 (40,2-74,2 Kg/m2)], acompanhados previamente em consultas de Nutrição e/ou Endocrinologia. Já tinham sido submetidos a medidas higieno-dietéticas e/ou farmacológicas, com sucesso limitado. Observadas co-morbilidades em 13 (76,5%).
Resultados: Oito (47%) doentes apresentaram náuseas/vómitos nas 24-72h seguintes situação que se manteve em 4 (23,5%), condicionando desidratação e insuficiência renal aguda pré-renal, obrigando à remoção precoce do balão (0,5 a 4 meses). Nos restantes doentes o BIG foi removido aos 6 meses (num aos 10). Todos os doentes perderam peso (5-70 Kg); perda média-19,6 Kg (p<0,001). Sem casos de rotura espontânea. Seis (35,3%) foram posteriormente operados.
Conclusões: O BIG é um método eficaz na redução de peso em indivíduos com obesidade mórbida. As náuseas e os vómitos são as complicações mais comuns. Embora desejável nem sempre se consegue a transposição para a cirurgia.
]]> Summary
Introduction: In patients with morbid obesity the intragastric balloon (IGB) can be a “bridge” to surgery or a temporary treatment in patients who are not candidates for surgery.
Objective: Evaluate IGB efficacy in morbidly obese patients.
Patients and Methods: In 2003/2004 seventeen IGB Bioenterics ® filled with normal saline and methylene blue were placed in 17 patients [11 women, median age was 49.2 (27-69 years); median body mass index was 55.6 (40.2-74.2 Kg/m2)], followed by nutritionists and/or endocrinologists. They had previously tried dietetic and/or pharmacological measures with limited results. Co-morbidities were present in 13 (76.5%).
Results: Eight (47%) patients presented nausea/vomiting in the first 24-72h that persisted in 4 (23.5%) leading to dehydration and pre-renal insufficiency and forcing premature removal of the balloon (0.5 to 4 months). In the other patients, the device was removed at 6 months treatment (in 1 patient at 10 months). All patients suffered weight loss (5-70 Kg); median loss-19.6 Kg (p<0.001). No cases of spontaneous deflation/displacement occurred. Six (35.3%) underwent bariatric surgery.
Conclusions: The IGB is a useful method for weight loss in morbidly obese patients. Nausea and vomiting are the most common complications. Although desirable, subsequent surgery is not always performed.
Texto Completo disponível apenas em PDF
Full text only available in PDF format
]]> Bibliografia
1. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997; 53: 238-52 [ Links ]
2. WHO Update: controlling the global obesity epidemic. http://www.who.int/nut/obs.html
3. Carmichael AR. Current concepts: Treatment for morbid obesity. Postgrad Med J 1999; 75: 7-12
4. Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-85
5. Shaper GA, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke and diabetes mellitus in a cohort study of middle aged men. BMJ 1997; 314: 1311-7
6. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289: 187
7. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO/NUT/NCD/98.1. WHO Technical Support Series, WHO, Geneva; 1998, p. 1-276
8. Herron DM. The surgical management of severe obesity. The Mount Sinai J of Med 2004; 71: 63-71
9. Doldi SB, Micheletto G, Perrini MN, Rapetti R. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology 2004; 51(55): 294-7
]]> 10. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61: 19-2711. Ulicny KS Jr, Goldberg SJ, Harper WJ, Korelitz JL, Podore PC, Fegelman RH. Surgical complications of the Garren-Edwards Gastric Bubble. Surg Gynecol Obstet 1988; 166: 535-40
12. Evans JD, Scott MH. Intragastric balloon for treatment of morbid obesity. Brit J of Surg 2001; 88: 1245-48
13. Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric balloon therapy. Obes Surg, 1999; 9: 261-4
*Correspondência:
Nuno Almeida
Serviço de Gastrenterologia
Hospitais da Universidade de Coimbra
Avenida Bissaya Barreto e Praceta Mota Pinto
]]> 3000-075 CoimbraTel.: 239400438; Fax: 239482805
e-mail: nuno.p.almeida@clix.pt
(1) Serviço de Gastrenterologia, HUC, Coimbra, Portugal.
(2) Serviço de Gastrenterologia, Hospital de Santo André, Leiria, Portugal.
(3) Serviço de Cirurgia 2, HUC, Coimbra, Portugal.
]]> Recebido para publicação: 15/12/2005
Aceite para publicação: 26/07/2006
]]>